Tetra Bio-Pharma signs agreement for exclusive use of Health Canada licensed facility with Quantum Pharma.
Tetra Bio-Pharma (TSXV:TBP) signs agreement for exclusive use of Health Canada licensed facility with Quantum Pharma.
As quoted in the press release:
Tetra Bio-Pharma and Quantum Pharma today announced the signing of a binding proposal for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations. Quantum Pharma owned by Dr. Peter Ford was the GMP manufacturing division of Ford’s Family Pharmacy and Wellness Centre. Their formulation expertise will enable Tetra to develop innovative products for future clinical trials.
Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are very pleased to announce this important development to our shareholders. We have been working with Ford’s Family Pharmacy and Wellness Centre since 2016. Dr. Peter Ford and his team have created several innovative formulations and instruments for the fabrication of Tetra’s prescription drugs. This exclusive agreement not only secures the innovations and production know-how developed for Tetra, but also protects these assets from an acquisition by a competitor. Quantum Pharma will be an exclusive partner to Tetra and Panag enabling us to execute our future planned trials as well as prepare for our product launches.”